Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Ascentage Pharma Group International ( (HK:6855) ) has issued an announcement.
Ascentage Pharma Group International will present four preclinical studies at the American Association for Cancer Research 2026 Annual Meeting, highlighting three key drug candidates: olverembatinib, APG-2449, and APG-5918. The data underscore the company’s strategy of using targeted and combination therapies to address resistance mechanisms and expand its oncology footprint.
The preclinical results show olverembatinib demonstrating strong antitumor activity and synergy with chemotherapy in endometrial carcinoma models, and with BTK inhibitor acalabrutinib in mantle cell lymphoma models. Alongside evaluations of APG-2449 in BRAF-mutant tumors and APG-5918 in small-cell lung cancer, these findings are expected to guide future clinical development and support ongoing global registrational efforts aimed at patients with limited treatment options.
The most recent analyst rating on (HK:6855) stock is a Buy with a HK$93.00 price target. To see the full list of analyst forecasts on Ascentage Pharma Group International stock, see the HK:6855 Stock Forecast page.
More about Ascentage Pharma Group International
Ascentage Pharma Group International is a Hong Kong-listed biopharmaceutical company focused on developing targeted therapies for cancer and other diseases with significant unmet medical needs. Its pipeline includes novel kinase inhibitors such as olverembatinib, APG-2449, and epigenetic modulator APG-5918, with a strategic emphasis on overcoming drug resistance and expanding indications beyond existing approvals.
Average Trading Volume: 2,073,352
Technical Sentiment Signal: Buy
Current Market Cap: HK$19.67B
Learn more about 6855 stock on TipRanks’ Stock Analysis page.